European Alpha-1 Research Collaboration (EARCO)
Who is this for?
Those with severe AATD, defined by an AAT serum level < 11 μM (50 mg/dl) and/or a proteinase inhibitor; genotype ZZ, SZ, and compound heterozygotes or homozygotes of other rare deficient variants (non-M)
Study:
EARCO collects prospective, non-interventional, multi-centre, standardized, longitudinal data on an international level necessary to evaluate the natural history of the disease; the influence of risk factors; other genetic determinants and the role of augmentation therapy in the prognosis of the disease elements